ArticleLipids in health and disease2025
Expression of cell-surface activation markers on human CD15
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Live AirwayEnvironment & health (Washington, D.C.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCell surface marker (CD) expressions and membrane lipid changes characterise circulating neutrophil transmigration into inflammation sites. Specific CD expressions mandate neutrophil activation. Lipid changes alter membrane fluidity, deformability, cell spreading and transmigration. Circulating neutrophil, predominantly CD15 positive (CD15+), recruitment to the lungs and activation is a crucial innate immune response in Acute Respiratory Distress Syndrome (ARDS) pathology. During transmigration, their membrane lipids rapidly acquire significant whole cell arachidonic acid enrichment. The source of arachidonate is unclear but neutrophils incorporate non-esterified fatty acids (NEFA) from their microenvironment, adjusting cellular fatty acyl-CoA pools. We hypothesised that inflammation-associated, specific NEFA incorporation(s) into neutrophil membrane lipids mandate activation. We evaluated patterns of synthesis, composition and turnover of phosphatidylcholine (PC), alongside transmigration markers, following NEFA supplementations of freshly isolated human CD15+ cells.
methodsCD15+ cells were collected from venous blood samples of 5 healthy volunteers using the autoMACS system with CD15+ microbeads. Isolated CD15+ cells were incubated for 3 h with methyl-D9-choline chloride. NEFA supplements were added separately or in combination. Modified Bligh and Dyer lipid extracts were analysed by mass spectrometry. Unlabelled PC composition was determined by precursor scans of the m/z + 184 and the deuteriated m/z + 193 fragment was used to report newly synthesised methyl-D9-choline labelled PC.
resultsFour NEFAs were chosen, oleic acid, linoleic acid, palmitic acid and arachidonic acid. All supplementations downregulated CD62L expression and increased expressions of CD11a and CD11b, hallmarks of activation. Membrane PC composition consisted of di-acyl species (59%) and alkylacyl PC species (41%), primary PC being PC34:1. Incorporation of methyl-D9-into polyunsaturated PC species was consistently elevated compared with endogenous composition. NEFA supplementations did not change bulk endogenous PC composition. There was lower fractional methyl-D9 enrichment with oleic acid compared to other NEFAs and the fractional enrichment varied between individual species.
conclusionsCD15+ microenvironmental exposure to every NEFA investigated resulted in expression of cellular activation markers. NEFA-defined changes in synthesis patterns of individual molecular species of membrane PC were consistent with membrane fluidity changes facilitating recruitment of activation markers and transmigration. Data suggest that altered neutrophil exposure to NEFA in vivo may potentially regulate their immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.